Lebrikizumab is comparable or superior to many advanced systemic monotherapies for the short-term treatment of atopic dermatitis.

The plant will have an annual capacity of 10,000 electric buses and 5,000 electric trucks, alongside a ecosystem for EV ...

Results from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Tralokinumab is effective in severe atopic dermatitis for up to 18 months, with patients who are naïve to some medications having faster benefits.

Future Markets Research Releases a Report on Noa Lithium Brines Inc (TSXV: NOAL)*. NOA Lithium operates at the nexus of several transformative global trends, including the clean energy transition, ...

I found myself wandering the streets of Johannesburg, unsure of what to expect but eager to see the story behind one of South ...

Natacha Tofield-Pasche, its project manager, said that besides the rising lake temperatures, global warming also leads to ...

A new report by the Central Pollution Control Board (CPCB), submitted to the National Green Tribunal (NGT), has declared the ...

Chinese electric vehicle manufacturers are gearing up for accelerated growth in the Australian market, as Canberra ramps up ...

Through investment in technologies and expertise, proper regulations and collaboration between African governments and other actors, the continent can embark on a solid energy transition ...

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal ...